In the development of tumors, abnormal activation of EGFR may initiate the related signaling pathways such as an ERBB-signaling pathway and the downstream ERBB pathways including RAS/ERK, PI3K/AKT or Wnt signaling (myc), ultimately promoting tumor occurrence and progression [30–35]. Here, MYC is linked to neoplasm.